CareDx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CareDx, Inc. (CDNA) on October 22, 2025. The filing reports the appointment of a new member to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
On October 22, 2025, the Board of Directors appointed Suresh Gunasekaran as a Class II director. Mr. Gunasekaran brings extensive healthcare executive experience, having served as CEO and President of UCSF Health since March 2022. Prior roles include CEO of University of Iowa Hospitals & Clinics and various leadership positions at UT Southwestern Medical Center.
Compensation and Governance Details
- Annual Cash Retainer: $50,000, paid quarterly (electable in cash or stock).
- Initial Equity Grant: Restricted Stock Units (RSUs) with a grant date fair value of $400,000, vesting in three equal annual installments.
- Annual Equity Grant: Automatic RSU awards with a grant date fair value of $225,000, vesting in one installment.
- Committee Assignments: No final determination has been made regarding specific Board committee assignments.
- Indemnification: An indemnification agreement was executed in the standard form used for other directors.
Investor Verification Checklist
- Verify the exact number of shares issued for the $400,000 initial RSU grant based on the stock price on October 22, 2025.
- Confirm the specific vesting schedule dates for the initial and annual RSU grants.
- Monitor future filings for Mr. Gunasekaran's specific committee assignments (e.g., Audit, Compensation, Nominating).
- Review the Company's 2024 Equity Incentive Plan to confirm remaining share availability for these grants.